We believe this site might serve you best:

United States

English Continue

This country code will remain if no action is taken to change it.

Don't see your country?
Promega Corporation

The Predictive Nature of High-Throughput Toxicity Screening Using a Human Hepatocyte...

The Predictive Nature of High-Throughput Toxicity Screening Using a Human Hepatocyte Cell Line
  • Print
  • Email
  • Download PDF

Abstract

Drug discovery has become an industrialized process in which vast libraries of compounds are screened for activity against a chosen target. The wealth of active compounds that emerge from these primary screens has created a bottleneck in drug development. First-round hits do not often meet the safety and efficacy criteria required for human therapeutics, so sequential rounds of optimization are required before a product can be administered to humans. Optimization requires assays that test Absorption, Distribution, Metabolism, Elimination and Toxicity. In this paper we demonstrate the utility of high-throughput testing in a human liver cell line. If the technologies and reagents presented in this article had been available earlier, ADME/Tox screening could have prevented deaths and costly drug recalls by two major pharmaceutical companies.

Cell Notes 3, 7–10.

Norman L. Sussman1, Monika Waltershield1, Terolyn Bulter1, James J. Cali2, Terry Riss2, and James H. Kelly1

1Amphioxus Cell Technologies, 2Promega Corporation
Publication Date: 2002

It appears that you have Javascript disabled. Our website requires Javascript to function correctly. For the best browsing experience, please enable Javascript.

Scientists at Your Service

Scientists at Your Service

We offer a range of services to help you succeed using Promega technologies. From product training to set up of automated systems and development of custom applications—our scientific support goes beyond the basics.

Ask us! We are here to help you.